Home  |  Contact

Cellosaurus WM902B (CVCL_6807)

[Text version]

Cell line name WM902B
Synonyms WM-902B; WM 902B; WM 902 B; WML 902B; WC00083
Accession CVCL_6807
Resource Identification Initiative To cite this cell line use: WM902B (RRID:CVCL_6807)
Comments Part of: Wistar Institute melanoma cell line collection.
Omics: Transcriptome analysis.
Sequence variations Heterozygous for BRAF p.Val600Glu (c.1799T>A) (Wistar; PubMed=18632627; PubMed=21156289).
CDK4 p.Arg24Leu (c.71G>T) (Wistar; PubMed=21156289).
Hemizygous for PTEN deletion (Wistar).
HLA typing Source: PubMed=15592718
Class I
HLA-AA*01:01,29:01
HLA-BB*07:02,08:01
HLA-CC*07:01:01,15:05
Class II
HLA-DPDPB1*04:01,02:01:02
HLA-DQDQB1*03:01:01,04:02
HLA-DRDRB1*08:01,11:01
Disease Melanoma (NCIt: C3224)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Hierarchy Children:
CVCL_VK52 (WM902B-BR)
Sex of cell Male
Age at sampling Age unspecified
Category Cancer cell line
STR profile Source(s): Wistar

Markers:
AmelogeninX,Y
CSF1PO11,12
D2S133817,24
D3S135815
D5S81812
D7S82011
D8S117912,14
D13S31712
D16S53911,13
D19S43312,13
D21S1128,30
FGA19
TH016,8
TPOX8,9
vWA15,16

Run an STR similarity search on this cell line
Web pages https://www.wistar.org/our-scientists/meenhard-herlyn
http://www.rockland-inc.com/Product.aspx?id=51955
Publications

PubMed=4053039
Herlyn M., Thurin J., Balaban G., Bennicelli J.L., Herlyn D., Elder D.E., Bondi E., Guerry D. IV, Nowell P.C., Clark W.H., Koprowski H.
Characteristics of cultured human melanocytes isolated from different stages of tumor progression.
Cancer Res. 45:5670-5676(1985)

PubMed=2253310; DOI=10.1007/BF00046337
Herlyn M.
Human melanoma: development and progression.
Cancer Metastasis Rev. 9:101-112(1990)

PubMed=2068080; DOI=10.1073/pnas.88.14.6028
Cornil I., Theodorescu D., Man S., Herlyn M., Jambrosic J.A., Kerbel R.S.
Fibroblast cell interactions with human melanoma cells affect tumor cell growth as a function of tumor progression.
Proc. Natl. Acad. Sci. U.S.A. 88:6028-6032(1991)

PubMed=15592718; DOI=10.1007/s00262-004-0561-5
Rodriguez T., Mendez R., Roberts C.H., Ruiz-Cabello F., Dodi I.A., Lopez Nevot M.A., Paco L., Maleno I., Marsh S.G.E., Pawelec G., Garrido F.
High frequency of homozygosity of the HLA region in melanoma cell lines reveals a pattern compatible with extensive loss of heterozygosity.
Cancer Immunol. Immunother. 54:141-148(2005)

PubMed=18632627; DOI=10.1158/0008-5472.CAN-08-0235
Smalley K.S.M., Contractor R., Nguyen T.K., Xiao M., Edwards R., Muthusamy V., King A.J., Flaherty K.T., Bosenberg M., Herlyn M., Nathanson K.L.
Identification of a novel subgroup of melanomas with KIT/cyclin-dependent kinase-4 overexpression.
Cancer Res. 68:5743-5752(2008)

PubMed=18790768; DOI=10.1158/1535-7163.MCT-08-0431
Smalley K.S.M., Lioni M., Dalla Palma M., Xiao M., Desai B., Egyhazi S., Hansson J., Wu H., King A.J., Van Belle P., Elder D.E., Flaherty K.T., Herlyn M., Nathanson K.L.
Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E-mutated melanomas.
Mol. Cancer Ther. 7:2876-2883(2008)

PubMed=21156289; DOI=10.1016/j.ccr.2010.11.023
Villanueva J., Vultur A., Lee J.T., Somasundaram R., Fukunaga-Kalabis M., Cipolla A.K., Wubbenhorst B., Xu X., Gimotty P.A., Kee D., Santiago-Walker A.E., Letrero R., D'Andrea K., Pushparajan A., Hayden J.E., Brown K.D., Laquerre S.G., McArthur G.A., Sosman J.A., Nathanson K.L., Herlyn M.
Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K.
Cancer Cell 18:683-695(2010)

Cross-references
Cell line collections Coriell; WC00083 - Discontinued
Cell line databases/resources ESTDAB; ESTDAB-085 - Discontinued
GDSC; 1240227
Ontologies BTO; BTO:0005780
Gene expression databases GEO; GSM186501
GEO; GSM186502
GEO; GSM952591
Other Wikidata; Q54994340
Polymorphism and mutation databases Cosmic; 686398
Cosmic; 972273
Cosmic; 1155282
Cosmic; 1155553
Cosmic; 1187581
Cosmic; 2163812